Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections
- PMID: 1387805
- DOI: 10.1093/clinids/15.2.285
Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections
Abstract
Seven patients with staphylococcal neurosurgical shunt infections were treated with intraventricular teicoplanin. Two infants received 5 mg/d, three patients received 20 mg/d, and two patients received 20 mg every other day. Six of these patients also received intravenous antibiotics. Three patients had infections caused by methicillin-susceptible Staphylococcus epidermidis, and one patient had an infection caused by methicillin-resistant S. epidermidis. Three patients were infected with Staphylococcus aureus (one with a methicillin-resistant strain and two with methicillin-susceptible strains). The mean duration of intraventricular therapy was 16 days. Sterilization of cerebrospinal fluid (CSF) was obtained after an average of 4.4 days. All patients were cured both clinically and microbiologically. No significant adverse effects were observed in any patients. Penetration of teicoplanin into the CSF after intravenous administration was poor. However, after intraventricular administration, high and prolonged peak and trough levels of teicoplanin were detected in the CSF. Bactericidal activity of the CSF was remarkable, exceeding the 1:8 dilution in the majority of the cases. The alternate-day schedule of intraventricular administration of teicoplanin was as effective as the once-daily regimen.
Similar articles
-
Teicoplanin in the therapy of staphylococcal neuroshunt infections.Int J Clin Pharmacol Res. 1987;7(3):207-13. Int J Clin Pharmacol Res. 1987. PMID: 2954919
-
Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.J Antimicrob Chemother. 1989 Jan;23(1):131-42. doi: 10.1093/jac/23.1.131. J Antimicrob Chemother. 1989. PMID: 2526109
-
Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.J Antimicrob Chemother. 1987 Sep;20(3):431-8. doi: 10.1093/jac/20.3.431. J Antimicrob Chemother. 1987. PMID: 2960643
-
Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.Drugs. 1990 Sep;40(3):449-86. doi: 10.2165/00003495-199040030-00007. Drugs. 1990. PMID: 2146108 Review.
-
[Antibiotic therapy of infected cerebrospinal fluid in hydrocephalus treated by a shunt].An Esp Pediatr. 1988 Dec;29(6):435-9. An Esp Pediatr. 1988. PMID: 3072889 Review. Spanish.
Cited by
-
2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.Clin Infect Dis. 2017 Mar 15;64(6):e34-e65. doi: 10.1093/cid/ciw861. Clin Infect Dis. 2017. PMID: 28203777 Free PMC article.
-
Treatment of cerebrospinal fluid shunt infections with teicoplanin.Eur J Clin Microbiol Infect Dis. 1994 Dec;13(12):1056-8. doi: 10.1007/BF02111827. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7889968
-
Intrathecal Antibacterial and Antifungal Therapies.Clin Microbiol Rev. 2020 Apr 29;33(3):e00190-19. doi: 10.1128/CMR.00190-19. Print 2020 Jun 17. Clin Microbiol Rev. 2020. PMID: 32349999 Free PMC article. Review.
-
Pharmacokinetics and pharmacodynamics of peptide antibiotics.Adv Drug Deliv Rev. 2022 Apr;183:114171. doi: 10.1016/j.addr.2022.114171. Epub 2022 Feb 18. Adv Drug Deliv Rev. 2022. PMID: 35189264 Free PMC article. Review.
-
Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.Pharmacoeconomics. 1995 Apr;7(4):357-74. doi: 10.2165/00019053-199507040-00009. Pharmacoeconomics. 1995. PMID: 10155323 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical